{
  "table_name": "quant_phosphoproteome_AML_ex_vivo_drug_response_sorafenib_treatment_pdc_current",
  "table_fullname": "isb-cgc-bq.CPTAC.quant_phosphoproteome_AML_ex_vivo_drug_response_sorafenib_treatment_pdc_current",
  "column_names": [
    "id_de_cas",
    "id_d_echantillon",
    "id_d_aliquote",
    "id_de_soumission_d_aliquote",
    "id_de_metadonnees_d_execution_d_aliquote",
    "nom_d_etude",
    "abondance_de_proteine_log2ratio",
    "id_refseq",
    "sites_de_phosphorylation"
  ],
  "column_types": [
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "FLOAT64",
    "STRING",
    "STRING"
  ],
  "nested_column_names": [
    "id_de_cas",
    "id_d_echantillon",
    "id_d_aliquote",
    "id_de_soumission_d_aliquote",
    "id_de_metadonnees_d_execution_d_aliquote",
    "nom_d_etude",
    "abondance_de_proteine_log2ratio",
    "id_refseq",
    "sites_de_phosphorylation"
  ],
  "nested_column_types": [
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "STRING",
    "FLOAT64",
    "STRING",
    "STRING"
  ],
  "description": [
    "Identifiant unique associé à un patient spécifique (e.g. 24cb0fcb-63d6-11e8-bcf1-0a2705229b82)",
    "Identifiant PDC unique pour cet échantillon (e.g. e8d83eb9-693a-11ea-b1fd-0aad30af8a83)",
    "Identifiant PDC unique pour cet aliquot (e.g. e8db124a-693a-11ea-b1fd-0aad30af8a83)",
    "ID de soumission d'aliquot attribué par le programme (e.g. T14)",
    "Identifie de manière unique l'aliquot en fonction de son utilisation dans l'expérience (en fonction du réactif d'étiquetage et/ou de la répétition biologique)",
    "Nom de l'étude (e.g. Étude pilote sur le cancer du cerveau pédiatrique - Phosphoprotéome)",
    "Rapport log-moyen des ions rapporteurs d'échantillon par rapport à la référence commune des ions de peptides associés au gène dans les acquisitions d'un échantillon biologique spécifique",
    "Identifiant unique donné à une séquence dans la base de données NCBI RefSeq",
    "Codes à lettre unique et positions de séquence de protéine des acides aminés phosphorylés (e.g. t304s310, t59)"
  ],
  "sample_rows": [
    {
      "id_de_cas": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
      "id_d_echantillon": "c00046d2-ffee-43d8-a72f-64a187590a7b",
      "id_d_aliquote": "d9a038c8-92b3-4fff-afeb-799d93b97841",
      "id_de_soumission_d_aliquote": "15-00276-1",
      "id_de_metadonnees_d_execution_d_aliquote": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
      "nom_d_etude": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
      "abondance_de_proteine_log2ratio": -2.4666,
      "id_refseq": "NP_000436.2",
      "sites_de_phosphorylation": "s1622"
    },
    {
      "id_de_cas": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
      "id_d_echantillon": "c00046d2-ffee-43d8-a72f-64a187590a7b",
      "id_d_aliquote": "d9a038c8-92b3-4fff-afeb-799d93b97841",
      "id_de_soumission_d_aliquote": "15-00276-1",
      "id_de_metadonnees_d_execution_d_aliquote": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
      "nom_d_etude": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
      "abondance_de_proteine_log2ratio": -4.905,
      "id_refseq": "NP_000923.1",
      "sites_de_phosphorylation": "s537"
    },
    {
      "id_de_cas": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
      "id_d_echantillon": "c00046d2-ffee-43d8-a72f-64a187590a7b",
      "id_d_aliquote": "d9a038c8-92b3-4fff-afeb-799d93b97841",
      "id_de_soumission_d_aliquote": "15-00276-1",
      "id_de_metadonnees_d_execution_d_aliquote": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
      "nom_d_etude": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
      "abondance_de_proteine_log2ratio": -4.0065,
      "id_refseq": "NP_001001.2",
      "sites_de_phosphorylation": "s235s236"
    },
    {
      "id_de_cas": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
      "id_d_echantillon": "c00046d2-ffee-43d8-a72f-64a187590a7b",
      "id_d_aliquote": "d9a038c8-92b3-4fff-afeb-799d93b97841",
      "id_de_soumission_d_aliquote": "15-00276-1",
      "id_de_metadonnees_d_execution_d_aliquote": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
      "nom_d_etude": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
      "abondance_de_proteine_log2ratio": -3.9549,
      "id_refseq": "NP_001005751.1",
      "sites_de_phosphorylation": "s1114"
    },
    {
      "id_de_cas": "ecbde1d1-d1d9-4de5-913d-090a0571edd9",
      "id_d_echantillon": "c00046d2-ffee-43d8-a72f-64a187590a7b",
      "id_d_aliquote": "d9a038c8-92b3-4fff-afeb-799d93b97841",
      "id_de_soumission_d_aliquote": "15-00276-1",
      "id_de_metadonnees_d_execution_d_aliquote": "0c7495c0-2773-4f0a-aef6-ad497c9e1249",
      "nom_d_etude": "AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome",
      "abondance_de_proteine_log2ratio": -3.2762,
      "id_refseq": "NP_001007027.1",
      "sites_de_phosphorylation": "s739s746s748"
    }
  ]
}